Pulse Biosciences Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan bought 205,127 shares of the firm’s stock in a transaction on Saturday, March 18th. The shares were acquired at an average cost of $23.56 per share, with a total value of $4,832,792.12. Following the purchase, the insider now directly owns 2,174,479 shares of the company’s stock, valued at approximately $51,230,725.24. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Shares of Pulse Biosciences Inc (NASDAQ:PLSE) traded down 5.96% during trading on Monday, hitting $23.03. 426,087 shares of the company’s stock were exchanged. Pulse Biosciences Inc has a one year low of $4.03 and a one year high of $25.15. The stock’s market cap is $306.62 million. The firm has a 50-day moving average price of $13.18 and a 200-day moving average price of $7.81.

Your IP Address:

Pulse Biosciences Company Profile

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

5 Day Chart for NASDAQ:PLSE

Receive News & Stock Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related stocks with our FREE daily email newsletter.